Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemiaHagop M. Kantarjian, Jean‐Pierre J. Issa, Susan O’Brien et al.|Blood|2006Cited by 691
DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic SyndromesLanlan Shen, Jean‐Pierre J. Issa, Hagop M. Kantarjian et al.|Journal of Clinical Oncology|2009Cited by 359